The earnings call presented a mixed picture. While there were notable achievements in revenue growth, profit performance, and innovation, there were significant challenges in CAG Diagnostic revenue and Reference Laboratory performance due to macroeconomic pressures and sector headwinds. The updated guidance reflects caution due to these ongoing challenges.
Company Guidance
During the earnings call for IDEXX Laboratories on October 31, 2024, the company provided updated guidance reflecting a strong performance in the third quarter despite some macroeconomic pressures. IDEXX reported an overall revenue increase of 6% organically, with significant contributions from their Companion Animal Group (CAG) Diagnostic recurring revenues, which grew 7% organically, and a 13% organic growth in their water business. The company has adjusted its full-year organic revenue growth expectation to between 5.3% and 6%, factoring in continued macroeconomic pressures and severe weather impacts in the U.S. The updated guidance also reflects a projected operating margin of 28.7% to 29% and an EPS outlook of $10.37 to $10.53 per share. In terms of product innovation, IDEXX has secured nearly 700 orders for their new inVue Analyzer, positioning them for future growth in Enhanced Value Instrument (EVI) metrics. Despite some near-term pressures, IDEXX remains optimistic about their long-term growth prospects, driven by ongoing product innovation and a strong focus on raising standards of pet healthcare globally.
Overall Revenue Growth
IDEXX reported an overall revenue increase of 6% organically, with notable growth in the CAG Diagnostic recurring revenues at 7% and the water business at 13%.
Strong Profit Performance
IDEXX reported EPS of $2.80 per share in Q3, up 11% as reported and 12% on a comparable basis. Operating margins were 31.2% in the quarter, reflecting a 100 basis point year-on-year improvement.
Innovation and Expansion
IDEXX secured nearly 700 orders for the new inVue Analyzer, demonstrating strong market interest in upcoming innovations. The company also expanded three major corporate account relationships this year.
Water Business Growth
The water business experienced a 13% organic growth, supported by double-digit gains in the U.S. and continued solid growth in Europe.
---
Idexx Laboratories (IDXX) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IDXX Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 31, 2024
$451.08
$406.92
-9.79%
Aug 06, 2024
$455.08
$469.37
+3.14%
May 01, 2024
$492.76
$468.04
-5.02%
Feb 05, 2024
$527.14
$572.12
+8.53%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Idexx Laboratories (IDXX) report earnings?
Idexx Laboratories (IDXX) is schdueled to report earning on Feb 10, 2025, TBA Not Confirmed.
What is Idexx Laboratories (IDXX) earnings time?
Idexx Laboratories (IDXX) earnings time is at Feb 10, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.